Citations

Clear

948 citation(s) found for "Li, Bryan".

Normal pressure hydrocephalus
Klassen, Bryan T. , Ahlskog, J. Eric

Mayo Clinic

Neurology | August 22, 2011 | Volume: 77 | Issue: 12 | Pages: 1119-1125

10.1212/wnl.0b013e31822f02f5 | PMID 21849644 Get It

Technology for Enhancing Chest Auscultation in Clinical Simulation
Ward, Jeffrey J , Wattier, Bryan A

Mayo Clinic

Respiratory Care | June 13, 2011 | Volume: 56 | Issue: 6 | Pages: 834-845

10.4187/respcare.01072 | PMID 21333091 Get It

Quantitative EEG as a predictive biomarker for Parkinson disease dementia
Klassen, Bryan T. , Hentz, Joseph G. , Shill, Holly A. , Driver‐Dunckley, Erika , Evidente, Virgilio Gerald H. , Caviness, John N., Sabbagh, Marwan Noel , Adler, Charles H.

Mayo Clinic

Neurology | June 3, 2011 | Volume: 77 | Issue: 2 | Pages: 118-124

10.1212/wnl.0b013e318224af8d | PMID 21633128 Get It

Invasive Fibrous Thyroiditis (Riedel Thyroiditis): The Mayo Clinic Experience, 1976–2008
Fatourechi, Mitra M., McIver, Bryan, Sebo, Thomas J., Fatourechi, Vahab , Hay, Ian

Mayo Clinic

Thyroid® | May 13, 2011 | Volume: 21 | Issue: 7 | Pages: 765-772

10.1089/thy.2010.0453 | PMID 21568724 Get It

Background: Invasive fibrous thyroiditis (IFT) is the rarest form of thyroiditis, and reports are often limited to case reports and small case series. In this study, we aimed to summarize our institutional experience with IFT since 1976. Methods: We retrospectively reviewed the cases of all patients with IFT evaluated at Mayo Clinic, Rochester, Minnesota, from 1976 through 2008, with special emphasis on clinical presentation, associated risk factors, associated comorbid conditions, complications, and treatment. Results: Twenty-one patients met our inclusion criteria of (i) IFT confirmed by pathologic review at our institution and (ii) evidence of extension of fibrosis outside the thyroid capsule. Most patients (17, 81%) were women (mean age, 42 years). Presenting symptoms included pain (24%), dysphagia (33%), vocal cord paralysis (29%), and tracheal narrowing (48%). Three patients had associated hypoparathyroidism. Sixteen (76%) had a history of tobacco use, and 10 (48%) were current smokers. Fibrosing mediastinitis was present in four, orbital fibrosis in one, retroperitoneal fibrosis in three, and pancreatic fibrosis in one (38% had extracervical fibrotic processes). Eighteen patients had partial thyroidectomy, 7 (39%) of whom had surgical complications involving vocal cords and parathyroid. Two required tracheostomy. Thirteen had corticosteroid therapy; six received tamoxifen. There was no cause-specific mortality, and the fibrotic process stabilized or partially resolved in all patients. Conclusions: IFT often is associated with a systemic extracervical fibrotic process and tobacco use. Attempted thyroid resection often results in postoperative complications. Long-term follow-up showed no deaths from IFT and showed stability of the thyroiditis.
Integrated control of proliferation and differentiation of mesenchymal stem cells.
Filipak, Michiko, Estervig, David N., Tzen, Chin‐Yuan, Minoo, Parviz , Hoerl, Bryan J., Maercklein, Peter B., Zschunke, Michael A., Edens, Maryanne, Scott, R E

Mayo Clinic

Environmental Health Perspectives | April 29, 2011 | Volume: 80 | Issue: No issue available | Pages: 117-125

10.1289/ehp.8980117 | PMID 2647473 Get It

Longitudinal modeling of frontal cognition in APOE ε4 homozygotes, heterozygotes, and noncarriers
Caselli, Richard J. , Dueck, Amylou C. , Locke, Dona E.C. , Hoffman‐Snyder, Charlene R., Woodruff, Bryan K. , Rapcsak, Steven Z. , Reiman, Eric M. , Dueck, A. C. , Locke, Dona E C

Mayo Clinic

Neurology | April 18, 2011 | Volume: 76 | Issue: 16 | Pages: 1383-1388

10.1212/wnl.0b013e3182167147 | PMID 21502596 Get It

High-Flow Nasal Cannula Oxygen in Critically Ill Adults: Do the Nose or Lungs Know There's a Difference?
Wattier, Bryan A, Ward, Jeffrey J

Mayo Clinic

Respiratory Care | March 7, 2011 | Volume: 56 | Issue: 3 | Pages: 355-358

10.4187/respcare.01250 | PMID 21396331 Get It

Cerebrovascular risk factors and preclinical memory decline in healthy APOE ε4 homozygotes
Caselli, Richard J., Dueck, Amylou C. , Locke, Dona E.C. , Sabbagh, Marwan N. , Ahern, Geoffrey L., Rapcsak, Steven Z. , Baxter, Leslie C. , Yaari, R. , Woodruff, Bryan K. , Hoffman‐Snyder, Charlene , Rademakers, Rosa , Findley, Scott, Reiman, Eric M. , Baxter, Leslie C. , Dueck, A. C. , Locke, Dona E C

Mayo Clinic

Neurology | February 17, 2011 | Volume: 76 | Issue: 12 | Pages: 1078-1084

10.1212/wnl.0b013e318211c3ae | PMID 21325652 Get It

Randomized, Double-Blinded, Placebo-Controlled Crossover Trial of Treating Erectile Dysfunction with Sildenafil After Radiotherapy and Short-Term Androgen Deprivation Therapy: Results of RTOG 0215
Bruner, Deborah Watkins , James, J., Bryan, Charlene, Pisansky, Thomas M. , Rotman, Marvin, Corbett, Thomas, Speight, Joycelyn L., Byhardt, Roger W., Bentzen, Søren M. , Kachnic, Lisa A. , Berk, Lawrence , Sandler, Howard M. , Bruner, Deborah , Bentzen, Soren M

Mayo Clinic

The Journal of Sexual Medicine | January 14, 2011 | Volume: 8 | Issue: 4 | Pages: 1228-1238

10.1111/j.1743-6109.2010.02164.x | PMID 21235716 Get It

ABSTRACT Introduction Erectile dysfunction (ED) may be the most commonly observed adverse event (AE) associated with the combination of radiation therapy (RT) and androgen deprivation therapy (ADT). A significant number of men are trying phosphodiesterase type 5 inhibitors (PDE5s) such as sildenafil to treat ED, yet sildenafil studies to date shed little light on the response to ED after ADT. Aim The purpose of this trial was to evaluate sildenafil in the treatment of ED in prostate cancer patients previously treated with external beam RT and neoadjuvant and concurrent ADT. Methods In this randomized, double-blinded crossover trial, eligible patients received RT/ADT for intermediate risk prostate cancer and currently had ED as defined by the International Index of Erectile Function (IIEF). Patients were randomized to 12 weeks of sildenafil or placebo followed by 1 week of no treatment then 12 weeks of the alternative. Treatment differences were evaluated using a marginal model for binary crossover data. Main Outcome Measures The primary end point was improved erectile function, as measured by the IIEF. Results The study accrued 115 patients and 61 (55%) completed all three IIEF assessments. Sildenafil effect was significant (P = 0.009) with a difference in probabilities of erectile response of 0.17 (95% confidence interval: 0.06, 0.29), and 0.21 (0.06, 0.38) for patients receiving ≤120 days of ADT. However, as few as 21% of patients had a treatment-specific response, only improving during sildenafil but not during the placebo phase. Conclusions This is the first controlled trial to suggest a positive sildenafil response for ED treatment in patients previously treated with RT/ADT, however, only a minority of patients responded to treatment. ADT duration may be associated with response and requires further study. The overall low response rate suggests the need for study of additional or preventative strategies for ED after RT/ADT for prostate cancer.
Enhanced Survival in Locoregionally Confined Anaplastic Thyroid Carcinoma: A Single-Institution Experience Using Aggressive Multimodal Therapy
Foote, Robert L. , Molina, Julian R. , Kasperbauer, Jan L. , Lloyd, Ricardo V., McIver, Bryan, Grant, Clive S., Thompson, Geoffrey B. , Richards, Melanie L., Smallridge, Robert C., Bible, Keith C. , Morris, John C. , Hay, Ian

Mayo Clinic

Thyroid® | December 17, 2010 | Volume: 21 | Issue: 1 | Pages: 25-30

10.1089/thy.2010.0220 | PMID 21162687 Get It

Background: Historical outcomes in anaplastic thyroid carcinoma (ATC) are poor, with a median survival of only 5 months and <20% of patients surviving 1 year from diagnosis. We hypothesized that survival in newly diagnosed patients with stages IVA and IVB locoregionally confined ATC might be improved by utilizing an aggressive therapeutic approach, prioritizing both the eradication of disease in the neck and preemptive treatment of occult metastatic disease. Methods: Between January 1, 2003, and December 31, 2007, 25 new ATC patients were evaluated at our institution. Of these 25 patients, 10 (40%) had metastatic disease at diagnosis and therefore underwent palliative treatment, whereas 5 (20%) had regionally confined disease and desired treatment at their local medical facilities. The remaining 10 consecutive patients (40%) had regionally confined ATC and elected aggressive therapy combining individualized surgery (where feasible), intensity-modulated radiation therapy (IMRT), and radiosensitizing + adjuvant chemotherapy intending four cycles of docetaxel + doxorubicin. Outcomes were assessed on an intention to treat basis. Results: There were no deaths from therapy, but hospitalization was required in two patients (20%) because of treatment-related adverse events. Five patients (50%) are alive and cancer-free, all having been followed >32 months (range: 32–89 months; median: 44 months) with a median overall Kaplan–Meier survival of 60 months. Overall survival at 1 and 2 years was 70% and 60%, respectively, compared to <20% historical survival at 1 year in analogous patients previously treated with surgery and conventional postoperative radiation at our and other institutions. Conclusions: Although based upon a small series of consecutively treated patients, an aggressive approach combining IMRT and radiosensitizing plus adjuvant chemotherapy appears to improve outcomes, including survival in stages IVA and IVB regionally confined ATC, but remains of uncertain benefit in patients with stage IVC (metastatic) disease. Also uncertain is the optimal chemotherapy regimen to use in conjunction with IMRT. Further multicenter randomized trials are required to define optimal therapy in this rare but deadly cancer.